Characterization and standardization of Sabin based inactivated polio vaccine: Proposal for a new antigen unit for inactivated polio vaccines

被引：38

作者：

Westdijk, Janny ^{[1
]}

Brugmans, Debbie ^{[1
]}

Martin, Javier ^{[2
]}

van't Oever, Aart ^{[1
]}

Bakker, Wilfried A. M. ^{[1
]}

Levels, Lonneke ^{[3
]}

Kersten, Gideon ^{[1
]}

机构：

[1] Natl Inst Publ Hlth, Unit Vaccinol, NL-3720 AL Bilthoven, Netherlands

[2] Natl Inst Biol Stand & Controls, Potters Bar, Herts, England

[3] Netherlands Vaccine Inst, NL-3720 AL Bilthoven, Netherlands

来源：

VACCINE | 2011年 / 29卷 / 18期

关键词：

Inactivated polio vaccine; Sabin; Antigenicity; Immunogenicity; IMMUNOGENICITY; STRAINS; ASSAYS; IMMUNIZATION; BIRTH; RATS;

D O I：

10.1016/j.vaccine.2011.02.085

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

GMP-batches of Sabin-IPV were characterized for their antigenic and immunogenic properties. Antigenic fingerprints of Sabin-IPV reveal that the D-antigen unit is not a fixed amount of antigen but depends on antibody and assay type. Instead of the D-antigen unit we propose standardization of IPV based on a combination of protein amount for dose and D-antigenicity for quality of the vaccine. Although Sabin-IPV type 2 is less immunogenic than regular wild type IPV type 2, the immunogenicity (virus neutralizing titers) per microgram antigen for Sabin-IPV type 2 is in the same order as for wild type serotypes 1 and 3. The latter observations are in line with data from human trials. This suggests that a higher dose of Sabin-IPV type 2 to compensate for the lower rat immunogenicity may not be necessary. (C) 2011 Elsevier Ltd. All rights reserved.

引用

页码：3390 / 3397

页数：8

共 50 条

[31] Immunogenicity evaluation of primary polio vaccination schedule with inactivated poliovirus vaccines and bivalent oral poliovirus vaccine [J].

Xu, Jiawei ;

Liu, Yang ;

Qiu, Wei ;

Li, Wenwen ;

Hu, Xiaoxiao ;

Li, Xia ;

Fan, Qiang ;

Tang, Wenge ;

Wang, Yujie ;

Wang, Qing ;

Yao, Ning .

BMC INFECTIOUS DISEASES, 2024, 24 (01)

[32] Current and next-generation formulation strategies for inactivated polio vaccines to lower costs, increase coverage, and facilitate polio eradication [J].

Kumar, Prashant ;

Bird, Christopher ;

Holland, David ;

Joshi, Sangeeta B. ;

Volkin, David B. .

HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2023, 18 (07)

[33] Evaluation of the use of various rat strains for immunogenic potency tests of Sabin-derived inactivated polio vaccines [J].

Someya, Yuichi ;

Ami, Yasushi ;

Takai-Todaka, Reiko ;

Fujimoto, Akira ;

Haga, Kei ;

Murakami, Kosuke ;

Fujii, Yoshiki ;

Shirato, Haruko ;

Oka, Tomoichiro ;

Shimoike, Takashi ;

Katayama, Kazuhiko ;

Wakita, Takaji .

BIOLOGICALS, 2018, 52 :12-17

[34] Assessment of Strengths and Weaknesses of Inactivated Polio Vaccine Practices in Qasimabad, Pakistan [J].

Channa, Imdad Ali ;

Memon, Khalida Naz ;

Zaman, Nimra .

GLOBAL JOURNAL OF MEDICAL PHARMACEUTICAL AND BIOMEDICAL UPDATE, 2021, 16 (10) :1-10

[35] Immunogenicity of seasonal inactivated influenza and inactivated polio vaccines among children in Senegal: Results from a cluster-randomized trial [J].

Niang, Mbayame ;

Deming, Meagan E. ;

Goudiaby, Deborah ;

Diop, Ousmane M. ;

Dia, Ndongo ;

Diallo, Aldiouma ;

Ortiz, Justin R. ;

Diop, Doudou ;

Lewis, Kristen D. C. ;

Lafond, Kathryn E. ;

Widdowson, Marc-Alain ;

Victor, John C. ;

Neuzil, Kathleen M. .

VACCINE, 2020, 38 (47) :7526-7532

[36] The case for replacing live oral polio vaccine with inactivated vaccine in the Americas [J].

Alfaro-Murillo, Jorge A. ;

Avila-Aguero, Maria L. ;

Fitzpatrick, Meagan C. ;

Crystal, Caroline J. ;

Falleiros-Arlant, Luiza-Helena ;

Galvani, Alison P. .

LANCET, 2020, 395 (10230) :1163-1166

[37] Scale-down of the inactivated polio vaccine production process [J].

Thomassen, Yvonne E. ;

van 't Oever, Aart G. ;

Vinke, Marian ;

Spiekstra, Arjen ;

Wijffels, Rene H. ;

van der Pol, Leo A. ;

Bakker, Wilfried A. M. .

BIOTECHNOLOGY AND BIOENGINEERING, 2013, 110 (05) :1354-1365

[38] Thermostabilization of inactivated polio vaccine in PLGA-based microspheres for pulsatile release [J].

Tzeng, Stephany Y. ;

Guarecuco, Rohiverth ;

McHugh, Kevin J. ;

Rose, Sviatlana ;

Rosenberg, Evan M. ;

Zeng, Yingying ;

Langer, Robert ;

Jaklenec, Ana .

JOURNAL OF CONTROLLED RELEASE, 2016, 233 :101-113

[39] Impact of inactivated poliovirus vaccine on mucosal immunity: implications for the polio eradication endgame [J].

Parker, Edward P. K. ;

Molodecky, Natalie A. ;

Pons-Salort, Margarita ;

O'Reilly, Kathleen M. ;

Grassly, Nicholas C. .

EXPERT REVIEW OF VACCINES, 2015, 14 (08) :1113-1123

[40] Analysis of the transition from oral polio vaccine to inactivated polio vaccine for primary immunization in a hospital-based primary care practice [J].

Lakhiani, CN ;

Vivier, PM ;

Alario, AJ ;

Simon, P ;

Diana, BJ ;

Peter, G .

PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2000, 19 (06) :575-576

← 1 2 3 4 5 →